Earnings summaries and quarterly performance for Structure Therapeutics.
Executive leadership at Structure Therapeutics.
Board of directors at Structure Therapeutics.
Research analysts covering Structure Therapeutics.
Recent press releases and 8-K filings for GPCR.
Structure Therapeutics Closes Upsized Public Offering
GPCR
- Structure Therapeutics Inc. (NASDAQ: GPCR) announced the closing of its upsized underwritten public offering on December 11, 2025.
- The offering included 9,961,538 American depositary shares (ADSs) at $65.00 per ADS and 1,538,462 pre-funded warrants at $64.9999 per pre-funded warrant, with the full exercise of the underwriters’ option to purchase up to 1,500,000 additional ADSs.
- The offering generated approximately $747.5 million in gross proceeds for Structure Therapeutics, before deducting underwriting discounts, commissions, and offering expenses.
Dec 11, 2025, 9:01 PM
Structure Therapeutics Announces Proposed Public Offering of ADSs and Warrants
GPCR
- Structure Therapeutics announced a proposed underwritten public offering to issue and sell $500 million of American depositary shares (ADSs) or pre-funded warrants to purchase ordinary shares.
- The company expects to grant the underwriters a 30-day option to purchase up to an additional $75 million of ADSs or pre-funded warrants.
- The proposed offering is being made pursuant to an automatic shelf registration statement on Form S-3, which became effective upon filing with the SEC on August 6, 2025.
- Jefferies, Leerink Partners, Goldman Sachs & Co. LLC, Morgan Stanley, Guggenheim Securities, and BMO Capital Markets are acting as joint book-running managers for the proposed offering.
Dec 8, 2025, 9:01 PM
Structure Therapeutics Reports Positive Aleniglipron Phase 2b Data and Plans Phase 3 Advancement
GPCR
New Projects/Investments
Product Launch
- Structure Therapeutics Inc. (GPCR) reported positive topline data from its ACCESS clinical program for aleniglipron, an oral small molecule GLP-1 Receptor Agonist, demonstrating a placebo-adjusted mean weight loss of 11.3% (27.3 lbs) with the 120 mg dose in the Phase 2b ACCESS study and up to 15.3% (35.5 lbs) with the 240 mg dose in the exploratory ACCESS II study at 36 weeks.
- A lower 2.5 mg starting dose in the ACCESS Open Label Extension and Body Composition studies significantly improved tolerability, resulting in no adverse event-related treatment discontinuations.
- Aleniglipron exhibited a compelling safety profile, with no cases of drug-induced liver injury, persistent liver enzyme elevations, or QTc prolongation across all studies.
- The company plans to advance aleniglipron to Phase 3 clinical development by mid-2026, following a Type B End-of-Phase 2 meeting with the FDA in the first half of 2026.
- As of September 30, 2025, Structure Therapeutics had $799 million in cash.
Dec 8, 2025, 1:47 PM
GPCR Provides Update on Aleniglipron Obesity Program Studies
GPCR
New Projects/Investments
Guidance Update
- Aleniglipron, an oral small molecule GLP-1R agonist, demonstrated significant placebo-adjusted mean weight loss, achieving 11.3% at 120 mg in the Phase 2b ACCESS study and up to 15.3% at 240 mg in the Exploratory ACCESS II study.
- Interim data from the ACCESS Open Label Extension (OLE) showed no evidence of a weight loss plateau beyond 36 weeks, with continued weight reduction observed up to Week 44.
- Tolerability was improved with a lower 2.5 mg starting dose, leading to no treatment discontinuations due to adverse events after a median of approximately 10 weeks in the OLE and Body Composition studies.
- GPCR has a compelling data package to advance Aleniglipron into Phase 3, with an End of Phase 2 meeting with the FDA planned and Phase 3 API manufacturing completed.
Dec 8, 2025, 1:30 PM
Structure Therapeutics Announces Positive Eleniglipron Phase 2 Top-Line Results
GPCR
New Projects/Investments
Guidance Update
- Structure Therapeutics announced positive top-line results from its Eleniglipron Phase 2 ACCESS Program, an oral small molecule GLP-1 receptor agonist.
- In the core Phase 2b ACCESS study, Eleniglipron achieved 8.2%, 9.8%, and 11.3% placebo-adjusted weight loss at 45mg, 90mg, and 120mg doses, respectively, over 36 weeks. Higher doses in the exploratory ACCESS 2 study showed up to 15.3% placebo-adjusted weight loss at 240mg.
- The drug demonstrated a strong safety profile with no events of drug-induced liver injury, no off-target safety signals, and no QTc prolongation across over 500 patients. Tolerability improved significantly with a 2.5 mg starting dose, leading to zero AE-related discontinuations in early dosing phases.
- Eleniglipron is now considered Phase 3 ready, with plans to initiate the Phase 3 program using a 2.5 mg starting dose and an anticipated First Patient In (FPI) in mid-2026.
- Additionally, the company announced that the IND for ACCG2671, an oral small molecule amylin receptor agonist, has been cleared by the FDA, and Phase 1 initiation is underway.
Dec 8, 2025, 1:30 PM
Structure Therapeutics Announces Positive Phase 2b Eleniglipron Data and Phase 3 Readiness
GPCR
New Projects/Investments
- Structure Therapeutics reported positive top-line 36-week data from its Phase 2b ACCESS study for Eleniglipron, an oral GLP-1 small molecule, demonstrating placebo-adjusted weight loss of 8.2% (45mg), 9.8% (90mg), and 11.3% (120mg).
- Higher doses in the exploratory ACCESS 2 study showed increased efficacy, with placebo-adjusted weight loss reaching 15.3% at the 240mg dose at 36 weeks, with no weight loss plateau observed up to 44 weeks.
- Eleniglipron demonstrated a manageable tolerability profile, with a 10.4% treatment discontinuation rate due to adverse events in the ACCESS study, and a 2.5mg starting dose significantly improved tolerability, resulting in zero adverse event-related discontinuations in studies using this approach.
- The company is Phase 3 ready for Eleniglipron, planning to initiate pivotal studies in the summer of 2026 with a 2.5mg starting dose, following an FDA meeting in early 2026.
Dec 8, 2025, 1:30 PM
Structure Therapeutics Announces Positive Phase 2b Data for Eleniglipron and Phase 3 Readiness
GPCR
Product Launch
New Projects/Investments
- Structure Therapeutics announced that Eleniglipron, an oral GLP-1 receptor agonist, achieved 11.3% placebo-adjusted weight loss at 120 mg and 15.3% at 240 mg after 36 weeks in its Phase 2b ACCESS and exploratory ACCESS 2 studies, respectively.
- The studies demonstrated a manageable gastrointestinal adverse event profile, with an overall 10.4% treatment discontinuation rate in the core Phase 2b ACCESS study.
- A 2.5 mg starting dose significantly improved tolerability, resulting in zero AE-related discontinuations in the first 10 weeks in studies where it was used, and the company plans to initiate its Phase 3 program with this starting dose.
- Eleniglipron showed no evidence of weight loss plateau beyond 36 weeks and no events of drug-induced liver injury or off-target safety signals across all dose levels.
- The company is ready to advance Eleniglipron into Phase 3, with an FDA meeting scheduled for early 2026 and anticipated initiation of pivotal Phase 3 studies in mid-2026.
Dec 8, 2025, 1:30 PM
Structure Therapeutics Discusses Pipeline and Strategy at Cantor Global Healthcare Conference
GPCR
New Projects/Investments
- Structure Therapeutics is focused on developing oral small molecules for obesity and diabetes, anticipating that these will expand the market, particularly through primary care physicians.
- The company expects two data readouts for its lead oral GLP-1 molecule, aleniglapron, from the Access and Access 2 studies by the end of 2025.
- Structure Therapeutics also plans to advance its oral amylin small molecule (2671) into the clinic by the end of 2025, with potential for both monotherapy and combination use.
- The company announced three new studies for aleniglapron, including a switch study, a body composition study, and a study for individuals with type 2 diabetes and obesity, to inform its Phase 3 design and broaden its label.
- Structure Therapeutics is actively seeking a strategic partner for commercialization to help realize the full potential of aleniglapron across various indications beyond chronic weight management.
Sep 3, 2025, 8:56 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more